EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Molecular Classification of Gastric Cancer With Emphasis on PDL-1 Expression: The First Report From Iran

Fatemeh Amirmoezi, Bita Geramizadeh iD

Clinical Pathology · 2022-01 · 15

DOI: 10.1177/2632010x221096378 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pathology, online erschienen am 25.05.2022. Verfasst von Fatemeh Amirmoezi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Medical School of Shiraz University, Shiraz University of Medical Sciences, Shiraz, Iran. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Gastric cancer is one of the lethal cancers and there is no effective treatment for these patients and still, 5-year survival rate is about 25% to 30%. Finding reliable biomarkers for early-stage diagnosis, targeted therapy, and survival prediction is a priority in this cancer.

Objectives

In this study we were trying to know about the molecular classification of gastric cancers in a group of patients from the South of Iran. Patients and Methods: In a cross sectional study, 50 specimens of gastric cancer were selected that have enough tissue to be stained by immunohistochemistry (IHC). IHC was performed for Her-2, mismatch repair genes (MLH-1, MSH-2, MSH-6, and PMS-2), and PDL-1. Frequency of positive makers was compared with survival and outcome. Results and Conclusion: In our study, deficient MMR (dMMR) was detected in 4 patients (8.0%). PD-L1 expression in tumor cells (TC) was observed in 1 of 4 cases (25%) with PMS2 loss. However, PD-L1 in TCs and TILs (tumor infiltrating lymphocytes) was negative in 1 case with MLH1 loss and in 3 of 4 cases with PMS2 loss, which was not statistically significant. All of our 50 cases were positive for MSH2 and MSH6, 24% of which showed TCs with PDL-1 expression and 32% of them in TIL. HER2 was positive in 2 (2/50, 4.0%) cases, among which all of the cases were positive for PD-L1 expression in TCs and TILs, respectively. However, in HER2-negative group, 26.2% (11/42) and 28.6% (12/42) of tumors were positive for PD-L1 in TCs and TILs, respectively. The expression rate of PD-L1 in HER2 negative TCs was significantly higher than that in HER2 positive TCs ( P = .033). Immunohistochemistry for Her-2 was equivocal in 6 cases (12.0%) none of which expressed PD-L1 in tumor cells. In our study minimum and maximum survival times from detection of gastric cancer were 1 and 87 months, respectively. The mean ± SD and median ± SD of overall survival time were 30.69 ± 4.88 and 18 ± 1.45 months, respectively. One and 3-year survival rates of 40% and 24%, respectively. PD-L1 expression was not associated with survival, but its expression was associated with intestinal type Lauren classification and negative HER-2. PD-L1 positivity in tumor cells or tumor infiltrating lymphocytes was not an independent prognostic factor in gastric cancer.

Schlagwörter

Stichwörter der Autor:innen

Gastric adenocarcinomaMolecular classificationPDL1

Autor:innen und Institutionen

  • Department of Pathology, Medical School of Shiraz University, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

ORCID-Profile: Bita Geramizadeh

Zitieren

APA

Amirmoezi, F., & Geramizadeh, B. (2022). Molecular Classification of Gastric Cancer With Emphasis on PDL-1 Expression: The First Report From Iran. Clinical Pathology, 15. https://doi.org/10.1177/2632010x221096378

Vancouver

Amirmoezi F, Geramizadeh B. Molecular Classification of Gastric Cancer With Emphasis on PDL-1 Expression: The First Report From Iran. Clinical Pathology. 2022;15. doi:10.1177/2632010x221096378

BibTeX
@article{Amirmoezi2022,
  author = {Amirmoezi, Fatemeh and Geramizadeh, Bita},
  title = {Molecular Classification of Gastric Cancer With Emphasis on PDL-1 Expression: The First Report From Iran},
  journal = {Clinical Pathology},
  year = {2022},
  volume = {15},
  doi = {10.1177/2632010x221096378}
}
Kostenlos starten →